cytochrome c oxidase assembly factor COX15Genealiases: CEMCOX2 · HAS · MC4DN6
Q-omics provides the consensus-scored COX15 profile across patient tissues and cancer cell-line models. COX15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COX15 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, COX15 RNA expression shows 19,749 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where COX15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX15 survival associations across molecular data types. COX15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX15 RNA expression–survival associations across cancer types. High COX15 expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, SCLC, LGG and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COX15 RNA expression.
This table summarizes COX15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for COX15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX15 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, LUAD, CHOL and STAD. The THCA box plot shows higher COX15 RNA expression in normal versus tumor tissue (log2 FC = −0.721, t-test p < 0.001).
This table shows molecular features associated with COX15 in patient tissues and cancer cell lines. In patient samples, COX15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COX15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
